JP2018528191A - 抗体を生成する新規な方法 - Google Patents

抗体を生成する新規な方法 Download PDF

Info

Publication number
JP2018528191A
JP2018528191A JP2018508678A JP2018508678A JP2018528191A JP 2018528191 A JP2018528191 A JP 2018528191A JP 2018508678 A JP2018508678 A JP 2018508678A JP 2018508678 A JP2018508678 A JP 2018508678A JP 2018528191 A JP2018528191 A JP 2018528191A
Authority
JP
Japan
Prior art keywords
protein
peptogenic
antibody
alanine
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018508678A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528191A5 (enExample
Inventor
スティーブン アンダーソン，
スティーブン アンダーソン，
エリオット キャンベル，
エリオット キャンベル，
Original Assignee
ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー
ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー, ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー filed Critical ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー
Publication of JP2018528191A publication Critical patent/JP2018528191A/ja
Publication of JP2018528191A5 publication Critical patent/JP2018528191A5/ja
Priority to JP2022099482A priority Critical patent/JP2022123088A/ja
Priority to JP2025017152A priority patent/JP2025081372A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018508678A 2015-08-19 2016-08-18 抗体を生成する新規な方法 Withdrawn JP2018528191A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022099482A JP2022123088A (ja) 2015-08-19 2022-06-21 抗体を生成する新規な方法
JP2025017152A JP2025081372A (ja) 2015-08-19 2025-02-04 抗体を生成する新規な方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562207022P 2015-08-19 2015-08-19
US62/207,022 2015-08-19
PCT/US2016/047620 WO2017031353A1 (en) 2015-08-19 2016-08-18 Novel methods of generating antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022099482A Division JP2022123088A (ja) 2015-08-19 2022-06-21 抗体を生成する新規な方法

Publications (2)

Publication Number Publication Date
JP2018528191A true JP2018528191A (ja) 2018-09-27
JP2018528191A5 JP2018528191A5 (enExample) 2019-09-12

Family

ID=56802717

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018508678A Withdrawn JP2018528191A (ja) 2015-08-19 2016-08-18 抗体を生成する新規な方法
JP2022099482A Pending JP2022123088A (ja) 2015-08-19 2022-06-21 抗体を生成する新規な方法
JP2025017152A Pending JP2025081372A (ja) 2015-08-19 2025-02-04 抗体を生成する新規な方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022099482A Pending JP2022123088A (ja) 2015-08-19 2022-06-21 抗体を生成する新規な方法
JP2025017152A Pending JP2025081372A (ja) 2015-08-19 2025-02-04 抗体を生成する新規な方法

Country Status (5)

Country Link
US (2) US11384138B2 (enExample)
EP (1) EP3337822A1 (enExample)
JP (3) JP2018528191A (enExample)
CA (1) CA2995838A1 (enExample)
WO (1) WO2017031353A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023540082A (ja) * 2020-09-04 2023-09-21 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー ＳＡＲＳ－ＣｏＶ－２ワクチン及び抗体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7048608B2 (ja) 2016-08-15 2022-04-05 チルドレンズ メディカル センター コーポレーション Ａｐｏｍ－ｆｃ融合タンパク質、それとスフィンゴシン１－リン酸（ｓ１ｐ）との複合体、および血管疾患および非血管疾患を処置するための方法
AU2017366924A1 (en) 2016-12-01 2019-07-11 The Trustees Of Columbia University In The City Of New York Serological assay for Zika virus infection
CN111836646A (zh) * 2017-08-15 2020-10-27 儿童医学中心公司 Apom-fc融合蛋白及其用途
WO2019118918A1 (en) * 2017-12-15 2019-06-20 Aleta Biotherapeutics Inc. Cd19 variants
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
US12415847B2 (en) 2018-10-12 2025-09-16 Children's Medical Center Corporation ApoM-Fc fusion proteins for treating lung diseases
WO2020219896A1 (en) * 2019-04-26 2020-10-29 Beijing Xuanyi Pharmasciences Co., Ltd. Cd80 variant proteins and uses thereof
TW202116797A (zh) 2019-07-30 2021-05-01 大學健康網絡 Ｉｉ類ｍｈｃ分子及其使用方法
TWI881991B (zh) * 2019-07-30 2025-05-01 大學健康網絡 Ｉｉ類ｍｈｃ分子及其使用方法
CN110592032B (zh) * 2019-10-14 2021-04-13 北京理工大学 泛素连接酶Smurf1突变体、编码基因及用途
CN110760597B (zh) * 2019-11-22 2022-08-23 西北农林科技大学 一种检测黄牛ncstn基因拷贝数变异的方法及其应用
EP3845554A1 (en) * 2019-12-30 2021-07-07 Technische Universität Dortmund Method for determining 5-methylcytosine configurations in dna
WO2022076947A1 (en) * 2020-10-09 2022-04-14 The General Hospital Corporation Peptide inhibitors of glioma-associated oncogene derived from the coiled-coil dimerization domain of kif7
EP4305190A4 (en) 2021-03-11 2025-03-26 Iggenix, Inc. METHODS AND SYSTEMS FOR PREDICTING AN ALLERGIC REACTION
CN117482090A (zh) * 2023-11-07 2024-02-02 中国人民解放军空军军医大学 一种化合物在调节tgr5受体活性及其在神经保护或抑郁症治疗中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183484A1 (en) * 1998-10-09 2002-12-05 Torres Jose V. Immunogenic formulation and process for preparation thereof
JP2007530647A (ja) * 2004-04-01 2007-11-01 コミッサリア ア レネルジ アトミック 安定化Ｔａｔ抗原及び抗ＨＩＶワクチン接種のためのその使用
JP2010510994A (ja) * 2006-11-30 2010-04-08 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザワクチン製剤

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
EP0582595A1 (en) 1991-04-26 1994-02-16 Surface Active Limited Novel antibodies, and methods for their use
US5661133B1 (en) 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
ATE182651T1 (de) 1992-06-09 1999-08-15 Hoppe Ag Riegel und türschloss
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
EP1658772A3 (en) 1995-01-17 2007-01-17 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6511832B1 (en) 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
EP1278551A2 (en) 2000-04-21 2003-01-29 Vical Incorporated Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
US20080038280A1 (en) * 2004-10-14 2008-02-14 Government Of The United States Of America A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
US20110195089A1 (en) 2008-10-08 2011-08-11 The Adminstrators Of The Tulane Educational Fund Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
CN102060929A (zh) * 2010-06-07 2011-05-18 夏书奇 T细胞免疫平衡肽

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183484A1 (en) * 1998-10-09 2002-12-05 Torres Jose V. Immunogenic formulation and process for preparation thereof
JP2007530647A (ja) * 2004-04-01 2007-11-01 コミッサリア ア レネルジ アトミック 安定化Ｔａｔ抗原及び抗ＨＩＶワクチン接種のためのその使用
JP2010510994A (ja) * 2006-11-30 2010-04-08 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザワクチン製剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol. 9:4, JPN6020021819, 2013, pages 744 - 752, ISSN: 0004709188 *
J. MOL. BIOL., vol. 320, JPN6020021821, 2002, pages 343 - 357, ISSN: 0004709189 *
JOURNAL OF VIROLOGY, vol. 87, no. 19, JPN6021014074, 2013, pages 10855 - 10873, ISSN: 0004487995 *
PLOS ONE, vol. 10(3), JPN6021014076, 2015, pages 0119899, ISSN: 0004487996 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023540082A (ja) * 2020-09-04 2023-09-21 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー ＳＡＲＳ－ＣｏＶ－２ワクチン及び抗体
US12605438B2 (en) 2020-09-04 2026-04-21 Rutgers, The State University Of New Jersey SARS-CoV-2 vaccines and antibodies

Also Published As

Publication number Publication date
US20180244759A1 (en) 2018-08-30
US11384138B2 (en) 2022-07-12
CA2995838A1 (en) 2017-02-23
JP2025081372A (ja) 2025-05-27
US20230042877A1 (en) 2023-02-09
WO2017031353A1 (en) 2017-02-23
JP2022123088A (ja) 2022-08-23
EP3337822A1 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
JP2022123088A (ja) 抗体を生成する新規な方法
MacDonald et al. Structural and immunological characterization of recombinant 6-cysteine domains of the Plasmodium falciparum sexual stage protein Pfs230
KR20230005962A (ko) 베타코로나바이러스 예방 및 치료요법
US8741576B2 (en) Heteroclitic analogs and related methods
JP4238031B2 (ja) ワクチン
JP2024508762A (ja) 抗ｔｌ１ａ抗体組成物及び肺における治療方法
US20120302452A1 (en) Comparative ligand mapping from mhc class i positive cells
JP2010506926A (ja) Ｉｉ−Ｋｅｙ増強ワクチンの効力
US20250179143A1 (en) Systems and methods for chaperone-mediated ligand exchange on mhc-i and mhc-related molecules using chicken tapbpr
Alshammari et al. Targeted amino acid substitution overcomes scale-up challenges with the human C5a-derived decapeptide immunostimulant EP67
JP7329529B2 (ja) ヘマグルチニンを含む広範に防御的なワクチン組成物を生成する方法
US9474793B2 (en) Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus
Wolfowicz et al. Expression and immunogenicity of the major house dust mite allergen Der p 1 following DNA immunization
US20100112008A1 (en) Tuberculosis nucleic acids, polypeptides and immunogenic compositions
WO2022051549A1 (en) Sars-cov-2 vaccines and antibodies
EP2987502B1 (en) Peptide adjuvants
BRPI0417286A (pt) misturas de peptìdeos ou polipeptìdeo antigênicos, peptìdeos antigênicos, polipeptìdeo antigênico, misturas antigênicas, lipopeptìdeo, mixotopo, lipomixotopo, conjugado, composições imunogênicas, vacina contra malária, uso de uma mistura, soro policlonal, anticorpo humano recombinante, usos de uma composição, medicamento, métodos e kits para o diagnóstico in vitro de malária, seqüências de nucleotìdeo, vetor de clonagem e/ou expressão recombinante, uso de um vetor de expressão vacina de dna e célula hospedeira recombinante
JP2024511356A (ja) ワクチン組成物及びその使用方法
JP2022542120A (ja) 抗原性ポリペプチドおよびその使用方法
US10125173B2 (en) HIV-1 V3 mimotopes capable of inducing cross-clade neutralizing antibodies
RU2848314C1 (ru) Профилактика и лечение бетакоронавируса
US10273292B2 (en) Non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection
Devadas et al. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211015

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220621

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220621

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220714

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220805

C092 Termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C092

Effective date: 20220808

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220808

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220812